{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:09 23:24:50.411",
            "Expression": "mesenchymal Human Placenta Mesenchymal Stem Cells Derived Exosomes",
            "NStudiesAvail": 430269,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "BriefSummary",
                  "BriefTitle",
                  "CentralContactEMail",
                  "CentralContactName",
                  "CentralContactPhone",
                  "CentralContactPhoneExt",
                  "CentralContactRole",
                  "CollaboratorClass",
                  "CollaboratorName",
                  "CompletionDate",
                  "CompletionDateType",
                  "Condition",
                  "ConditionAncestorId",
                  "ConditionAncestorTerm",
                  "ConditionBrowseBranchAbbrev",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "BriefSummary": [
                              "Study aim:\n\nSafety of Human Placenta Mesenchymal Stem Cells Derived Exosomes for treatment of complex Anal Fistula 2.Efficacy of Human Placenta Mesenchymal Stem Cells Derived Exosomes for treatment of refractory Anal Fistula 3.Fistula changes in MRI studies, 12 weeks after treatment 4.Evaluation of quality of life in perianal fistula patient's questionnaire score before and 12 weeks after treatment\n\nParticipants/Inclusion and exclusion criteria:\n\ninclusion Criteria : 1.Age between 18-70 years old 2.Occurrence of complex perianal fistula 3.Informed consent Exclusion Criteria: 1.Active inflammatory bowel disease 2.Synchronous perianal abscess 3.Alcohol,narcotic and stimulant consumption 4.Having active Hepatitis B,C,HIV or TB 5.Peregnancy and lactation 6.Uncontrolled diabetes mellitus 7.Evidence of surgical contraindication 8.Psychological disorders and noncooperative patient\n\nIntervention groups:\n\nHuman Placenta Mesenchymal Stem Cells Derived Exosomes injected in fistula tract of patients with complex perianal Fistula in 3 weekly episodes and it's safety and efficacy was evaluated.\n\nDesign:\n\nthis study includes two separate groups of cases and controls each consisting of 40 participants randomly allocated for the phase 2 of clinical trial.\n\nSettings and conduct:\n\nPatients with complex perianal fistula referred to Imam Khomeini hospital, will be included in the study if they contain inclusion criteria. The fistula was evaluated by clinical examination and MRI and patients fill the quality of life questionnaire. Exosome injections are performed weekly for consecutive three weeks. Patients will reexamined and fill the questionnaire and MRI will done 12 weeks later. Recent findings will compare with the initial data. During this period, patients are examine for complications.\n\nMain outcome variables:\n\nDischarge amount; External orifice re-epithelialization ; Inflammation, discharge and abscess larger than 2 cm in MR imaging; Quality of life questionnaire score, Inflammatory markers such as CRP, IL-6, TNF-a, calprotectin"
                        ],
                        "BriefTitle": [
                              "Safety and Efficacy of Injection of Human Placenta Mesenchymal Stem Cells Derived Exosomes for Treatment of Complex Anal Fistula"
                        ],
                        "CentralContactEMail": [],
                        "CentralContactName": [],
                        "CentralContactPhone": [],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "August 22, 2022"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Fistula Perianal"
                        ],
                        "ConditionAncestorId": [
                              "D000020763",
                              "D000007412",
                              "D000016154",
                              "D000004066",
                              "D000007410",
                              "D000005767",
                              "D000012002"
                        ],
                        "ConditionAncestorTerm": [
                              "Pathological Conditions, Anatomical",
                              "Intestinal Fistula",
                              "Digestive System Fistula",
                              "Digestive System Diseases",
                              "Intestinal Diseases",
                              "Gastrointestinal Diseases",
                              "Rectal Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC23",
                              "All",
                              "BC06"
                        ],
                        "NCTId": [
                              "NCT05402748"
                        ]
                  },
                  {
                        "Rank": 2,
                        "BriefSummary": [
                              "Study aim:\n\nSafety of Human Placenta Mesenchymal Stem Cells Derived Exosomes for treatment of perianal fistula in patients with Crohn's disease 2. Efficacy of Human Placenta Mesenchymal Stem Cells Derived Exosomes for treatment of refractory Anal Fistula in patients with Crohn's disease 3. Fistula changes in MRI studies, 12 weeks after treatment 4. Evaluation of quality of life in perianal fistula patient's questionnaire score before and 12 weeks after treatment\n\nParticipants/Inclusion and exclusion criteria:\n\ninclusion criteria: 1. Age between 18-70 years old 2.Occurrence in patients with Crohn's disease 3. Informed consent Exclusion Criteria: 1. Active inflammatory bowel disease 2. Synchronous perianal abscess 3. Alcohol, narcotics and stimulant consumption 4. Having active Hepatitis B, C, HIV, or TB 5. Pregnancy and lactation 6.Uncontrolled diabetes mellitus 7. Evidence of surgical contraindication 8.Psychological disorders and noncooperative patient\n\nIntervention groups:\n\nHuman Placenta Mesenchymal Stem Cells Derived Exosomes injected in fistula tract of patients with complex perianal Fistula in 3 weekly episodes, and it's safety and efficacy were evaluated.\n\nDesign:\n\nthis study includes two separate groups of cases and controls, each consisting of 40 participants randomly allocated for phase 2 of a clinical trial.\n\nSettings and conduct:\n\nPatients with complex perianal fistula referred to Imam Khomeini hospital will be included in the study if they contain inclusion criteria. The fistula was evaluated by clinical examination, and MRI and patients fill the quality of life questionnaire. Exosome injections are performed weekly for three consecutive weeks. Patients will be reexamined and fill out the questionnaire, and MRI will be done 12 weeks later. Recent findings will compare with the initial data. During this period, patients are examined for complications.\n\nMain outcome variables:\n\nDischarge amount; External orifice re-epithelialization; Inflammation, discharge and abscess larger than 2 cm in MR imaging; Quality of life questionnaire score, Inflammatory markers such as CRP, IL-6, TNF-a, calprotectin"
                        ],
                        "BriefTitle": [
                              "Safety of Injection of Placental Mesenchymal Stem Cell Derived Exosomes for Treatment of Resistant Perianal Fistula in Crohn's Patients"
                        ],
                        "CentralContactEMail": [],
                        "CentralContactName": [],
                        "CentralContactPhone": [],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "September 2022"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Perianal Fistula in Patients With Crohn's Disease"
                        ],
                        "ConditionAncestorId": [
                              "D000015212",
                              "D000005759",
                              "D000005767",
                              "D000004066",
                              "D000007410",
                              "D000020763",
                              "D000007412",
                              "D000016154",
                              "D000012002"
                        ],
                        "ConditionAncestorTerm": [
                              "Inflammatory Bowel Diseases",
                              "Gastroenteritis",
                              "Gastrointestinal Diseases",
                              "Digestive System Diseases",
                              "Intestinal Diseases",
                              "Pathological Conditions, Anatomical",
                              "Intestinal Fistula",
                              "Digestive System Fistula",
                              "Rectal Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC23",
                              "All",
                              "BC06"
                        ],
                        "NCTId": [
                              "NCT05499156"
                        ]
                  }
            ]
      }
}